- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
45
45 companies
Travere Therapeutics
Market Cap: US$1.6b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$16.56
7D
-18.7%
1Y
138.3%
Alnylam Pharmaceuticals
Market Cap: US$34.5b
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference.
ALNY
US$262.16
7D
-3.3%
1Y
73.1%
Legend Biotech
Market Cap: US$6.1b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$32.88
7D
-7.1%
1Y
-40.4%
Blueprint Medicines
Market Cap: US$5.8b
A precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
BPMC
US$87.11
7D
-2.9%
1Y
-3.9%
Abeona Therapeutics
Market Cap: US$227.1m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.95
7D
-1.8%
1Y
-35.7%
Vanda Pharmaceuticals
Market Cap: US$263.0m
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
VNDA
US$4.37
7D
-5.0%
1Y
-11.2%
SpringWorks Therapeutics
Market Cap: US$3.5b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
SWTX
US$43.07
7D
-9.3%
1Y
-3.3%
OS Therapies
Market Cap: US$32.1m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.54
7D
-4.9%
1Y
n/a
Tenaya Therapeutics
Market Cap: US$91.4m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.52
7D
-24.8%
1Y
-88.6%
Madrigal Pharmaceuticals
Market Cap: US$7.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$327.10
7D
-3.0%
1Y
35.5%
RenovoRx
Market Cap: US$35.6m
A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.91
7D
-10.8%
1Y
-24.2%
Aldeyra Therapeutics
Market Cap: US$317.9m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$1.42
7D
-77.3%
1Y
-69.7%
Silence Therapeutics
Market Cap: US$136.5m
A biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
SLN
US$2.74
7D
-25.7%
1Y
-87.2%
Capricor Therapeutics
Market Cap: US$444.9m
A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
CAPR
US$9.27
7D
-21.5%
1Y
38.4%
Soleno Therapeutics
Market Cap: US$3.3b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$72.16
7D
0.2%
1Y
72.6%
Kiniksa Pharmaceuticals International
Market Cap: US$1.6b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$21.76
7D
-6.8%
1Y
20.5%
CollPlant Biotechnologies
Market Cap: US$29.5m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$2.46
7D
-7.2%
1Y
-53.2%
Precigen
Market Cap: US$435.2m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.34
7D
-18.3%
1Y
-1.5%
Arcutis Biotherapeutics
Market Cap: US$2.0b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$16.16
7D
0.4%
1Y
50.3%
aTyr Pharma
Market Cap: US$263.0m
A biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States.
ATYR
US$2.79
7D
-14.4%
1Y
49.2%
XOMA Royalty
Market Cap: US$236.9m
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
XOMA
US$19.81
7D
-5.5%
1Y
-23.2%
Invivyd
Market Cap: US$66.0m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$0.55
7D
-9.8%
1Y
-84.6%
BioRestorative Therapies
Market Cap: US$13.9m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.80
7D
-1.6%
1Y
34.3%
Chimerix
Market Cap: US$799.2m
A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
CMRX
US$8.53
7D
0.4%
1Y
720.2%
Unicycive Therapeutics
Market Cap: US$56.9m
A biotechnology company, develops treatments for various medical conditions in the United States.
UNCY
US$0.59
7D
-5.8%
1Y
-59.6%
ESSA Pharma
Market Cap: US$70.1m
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
EPIX
US$1.58
7D
2.6%
1Y
-80.6%
BeiGene
Market Cap: US$29.5b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$264.32
7D
0.7%
1Y
76.7%
Anavex Life Sciences
Market Cap: US$728.1m
A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
AVXL
US$8.30
7D
-13.0%
1Y
85.3%
Rhythm Pharmaceuticals
Market Cap: US$3.3b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$49.82
7D
-6.9%
1Y
24.2%
Vertex Pharmaceuticals
Market Cap: US$124.2b
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
VRTX
US$484.01
7D
-3.7%
1Y
19.8%
Ardelyx
Market Cap: US$1.2b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$4.74
7D
-7.8%
1Y
-33.8%
Rocket Pharmaceuticals
Market Cap: US$671.8m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$5.56
7D
-29.4%
1Y
-77.7%
Day One Biopharmaceuticals
Market Cap: US$807.8m
A commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$7.71
7D
-5.9%
1Y
-45.7%
Mirum Pharmaceuticals
Market Cap: US$2.2b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$43.23
7D
-6.2%
1Y
70.7%
Sierra Oncology
Market Cap: US$1.3b
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
SRRA
US$54.99
7D
0.06%
1Y
179.4%
GeoVax Labs
Market Cap: US$16.3m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
GOVX
US$1.10
7D
-13.4%
1Y
-45.3%